UBS Maintains Neutral on Calumet, Raises Price Target to $47

Benzinga Newsdesk www.benzinga.com Positive 72.4%

Neg 0% Neu 0% Pos 72.4%

UBS analyst Manav Gupta maintains Calumet (NASDAQ:CLMT) with a Neutral and raises the price target from $26 to $47.

Comments

No comments yet. Be the first!